

14 August 2007



***deltaDOT strengthens Board with appointment of two new non-executive directors***

**London, UK, 14 August 2007....** deltaDOT Ltd, a developer of innovative enabling molecular imaging technologies and products for bioscience research and production, has appointed Dr Peter Coggins and Ed Robinson as Non-Executive Directors to the Board. Both appointments add extensive sales, marketing and business development experience to deltaDOT's Board and will help to drive the commercial success of the company.

Dr Peter Coggins has over thirty years' experience in the biotechnology and life-science industry. He was previously President of Life and Analytical Sciences at PerkinElmer Inc and Executive Vice President of Global Sales at Amersham Biosciences. He currently sits on the Board of Directors of Biohit OYJ, Finland and is an advisory committee member to the US Secretary of Health. Dr Coggins has a BSc (Hons) and a PhD in Zoology from University of London.

Ed Robinson has extensive commercial and operations experience in the life sciences industry, having worked with both small start up companies and large multinationals. His most recent role was as Executive Vice President, Europe and Asia Pacific Pharma and Biopharmaceuticals at Cambrex Corporation and he has also previously held senior management roles at Solutia Inc, Lonza Biologics plc and Genencor International Inc. Mr Robinson holds a BSc in Marketing Management from Clarkson University and an MBA in Management from Rochester Institute of Technology.

Commenting on the new appointments, Dr Tony Baxter, CEO of deltaDOT said: "The appointment of Peter Coggins and Ed Robinson to our Board alongside Chairman, Dr Andrew Carr, previously CEO of Amersham Biosciences, underpins our strategy of bringing great technology to the market that addresses identified needs. With their marketing and sales experience they will help to drive the growth deltaDOT as we build on the success of our Peregrine protein analysis product and introduce our pipeline of advanced technologies and products to the market. I am delighted to welcome them to the Company."

**- ENDS -**

**High resolution images are available:**



Dr Peter Coggins



Ed Robinson

**Media Contact for deltaDOT:**

Lorna Cuddon, Gemma Price, Katie Odgaard

Tel: +44 (0)20 7268 3245

Email: [deltadot@northbankcommunications.com](mailto:deltadot@northbankcommunications.com)

**About deltaDOT Ltd**

deltaDOT ([www.deltadot.com](http://www.deltadot.com)) is a biotechnology company that is developing and commercialising highly innovative enabling technologies and products in the bioscience arena. The company was founded in 2000 and is a spin-out from Imperial College of Science, Technology and Medicine in London, UK. It is focused on the harnessing of cutting-edge particle physics technology and its application to the needs of biomolecular separation, including proteins, DNA and RNA analysis. The company has a strong proprietary position and extensive expertise in instrumentation, microfluidics, automation, computing and analysis which will contribute to improvements in knowledge, profitability and process time throughout drug discovery and general life sciences research.

**About Peregrine**

deltaDOT's primary product is Peregrine, a High Performance Capillary Electrophoresis instrument for the separation of proteins, peptides, nucleic acids, small molecules and pathogens. Launched in May 2006, Peregrine has been employed by customers in chemistry analysis, proteomics, biopharmaceutical QA/QC and fermentation laboratories in pharma, biotech and diagnostic businesses.

**About Label Free Intrinsic Imaging™ (LFIITM)**

deltaDOT's core technology, Label Free Intrinsic Imaging (LFIITM), coupled with proprietary powerful analyses, forms the basis of its product offering. LFIITM allows the direct monitoring of unlabelled biomolecules in real time, resulting in much faster, more accurate results at a fraction of the cost of conventional approaches. Other products being developed are Merlin®, a high throughput protein folding device, and systems capable of rapid, unbiased analysis of genomic, proteomic and chemical content of unknown substances and threats.